NASDAQ: BIIB
Biogen Inc.
Healthcare · Drug Manufacturers - General
After hours: $202.95(0%) · as of 7:34 PM ET
Market Cap
$29.99B
52w High
$219.72
52w Low
$124.56
P/E
36.14
Volume
1.03M
Outstanding Shares
147.75M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 58.55% over the last year. Revenue declined 0.49% over the trailing twelve months. Operating margin moved from 24.08% to 12.79%. Free cash flow grew 59.89% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 12.79%. A decisive move in revenue — currently down 0.49% — would be the clearest signal to resolve the ambiguity.
Company profile
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions.
Valuation
Stock splits
Every 1 shares became 3
Every 1 shares became 2
Profitability & growth
Analyst consensus
30
Buy
17
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Oct 29, 2026
Q4 FY26 · EPS est $2.24 · Revenue est $2.62B
View